Navigation Links
Despite FDA Warning, Avandia Use Varies Across U.S.
Date:11/18/2010

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, Nov. 17 (HealthDay News) -- Using the controversial diabetes drug Avandia as an example, new research finds that doctors' prescribing patterns vary across the country in response to warnings about medications from the U.S. Food and Drug Administration.

The result is that patients may be exposed to different levels of risk depending on where they live, the researchers said.

"We were looking at the impact black-box warnings for drugs have at a national level, and, more specifically, at a geographical level, and how these warnings are incorporated into practice," said study lead researcher Nilay D. Shah, an assistant professor of health services research at the Mayo Clinic in Rochester, Minn.

In 2007, the FDA required that Avandia come with a "black-box warning" -- the strongest warning possible -- alerting consumers that the drug was associated with an increased risk of heart attack.

Before the warning, Avandia was widely prescribed throughout the United States, although regional differences existed. "There was about a two-fold difference in use before the warning -- around 15.5 percent use in Oklahoma versus about 8 percent in North Dakota," Shah said.

Right after the warning, the use of Avandia dropped dramatically, from a nationwide high of 1.3 million monthly prescriptions in January 2007 to roughly 317,000 monthly prescriptions in June 2009.

"There was a huge decrease in use across the country," Shah said. "But there was quite a bit of residual use."

After the FDA warning, the researchers still found as much as a three-fold difference in use across the nation. In Oklahoma, Avandia use dropped to about 5.6 percent, but in North Dakota it tumbled to 1.9 percent, Shah said.

The reasons for the differences aren't clear. Some factors might include how doctors are made aware of FDA warnings and how they react. Another factor could be the policy of state health insurance plans, including Medicaid, in terms of covering drugs, he said.

Also, prominent doctors in given areas can influence the choice of drugs other doctors make, Shah said. And drug-company marketing may play a role, he said.

"At this point we don't have good insight into these differences," he said.

This problem isn't unique to Avandia, Shah said. "This is not uncommon with a lot of drugs," he said. "This is a good case example."

The report was published in the Nov. 17 edition of the New England Journal of Medicine.

The study also found that the American Diabetes Association's January 2009 consensus statement advising against prescribing Avandia appeared to have had a "negligible influence" on trends in its use.

The study authors think the FDA could do a better job of alerting all doctors about warning labels. "The FDA could provide a tool for doctors and patients to show the risks and benefits of going on the drug," Shah said.

As for Avandia, in September the FDA introduced further restrictions on use of the drug. The agency is requiring Avandia's maker, GlaxoSmithKline, to develop a program that will limit access to the drug to patients for whom other treatments have not worked.

Also, doctors will have to state and document a patient's eligibility to use Avandia. They will also have to tell patients about the cardiovascular safety risks associated with Avandia, and patients will have to acknowledge that they understand those risks.

Commenting on the new study, Dr. Luigi Meneghini, professor and director of clinical operations in the division of endocrinology, diabetes and metabolism at the University of Miami Miller School of Medicine, said "there was still some confusion about the negative effects of Avandia."

"Physicians tend to be skeptical and not change their habits unless there is solid evidence, and with Avandia the evidence was not as solid as one would want," he said. "But, for the majority of physicians there was clearly a change in the way they prescribe."

With the new restrictions the FDA has placed on Avandia, Meneghini believes that very few doctors will be prescribing the drug anymore.

Meneghini added that the FDA is pretty good at getting warning information out to doctors. "Whether the warning is heeded depends on the availability of the drug, the importance of the drug and patient desires," he said.

Also, many doctors stopped prescribing Avandia when the warning came out due to fear of liability, Meneghini said. "That drove a lot of the decisions," he said.

More information

For more on Avandia, visit the U.S. National Library of Medicine.

SOURCES: Nilay D. Shah, Ph.D., assistant professor of Health Services Research, Mayo Clinic, Rochester, Minn.; Luigi Meneghini, M.D., professor and director of clinical operations, division of endocrinology, diabetes and metabolism, University of Miami Miller School of Medicine; Nov. 17, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Race may influence uterine cancer recurrence, despite treatment
2. Despite highest health spending, Americans life expectancy falls behind other countries
3. Surf Sweets Among Few Candy Offerings Free of Synthetic Dyes Despite Growing Consumer Concern Over Affect on Children
4. Summer...Despite All the Fun it Can be a Headache How to Enjoy Your Summer Fun without the Aggravation of a Headache Seasonal Headache Relief Tips from Leading Neurolog
5. Summer...Despite All The Fun It Can Be A Headache
6. Despite food-assistance programs, many children experience food insecurity, hunger
7. Long-term use of anti-anxiety drugs continues in B.C. despite known health risks: UBC study
8. Lung disease may be genetic, despite lack of family history
9. A Tan Is Still Admired, Despite Risks
10. Despite tests, high blood pressure hard to recognize in children
11. Complex Spinal Operations Soar Despite Drawbacks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North Hollywood ... of February, patients who visit Hamlin Dental Group will receive a ticket for a ... the Cheesecake Factory. , Tickets are available for routine dental visits and other ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an approved content provider for the National Institute for Health and Care ... social care-related organizations in the National Health Service (NHS) to search, order and ...
(Date:2/23/2017)... ... ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice located at ... Top Patient Rated Henderson Dentist by Find Local Doctors earlier this year. ... dentists who have earned high ratings and superior patient reviews from multiple credible sources. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global data ... that Premier Research, a leading clinical development service provider, has selected ERT’s Trial ... complex, due in part to an array of circumstances including the use of ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... the pre-eminent publication and community for those in the fight against cancer, has ... important in their success. HRA will release top-line findings in a webinar, ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 9.2% over the next decade to reach approximately ... market estimates and forecasts for all the given segments on global ...
(Date:2/23/2017)... MIAMI , February 23, 2017 ML ... stake in Colorado Highlife Tours , a ... strategic plan in partnership with Puration, Inc. (USOTC: PURA) to enter ... luxury cannabis tours product. The Colorado Highlife Tours acquisition announced today ... cannabis tourism strategy. ...
(Date:2/23/2017)... The U.S. cannabis market is growing ... use in 2016. According to a new report published by ... estimated $7.2 billion in 2016 and is projected to grow ... recreational sales are projected to jump from $2.6 billion in ... The market may grow faster as the estimate was based ...
Breaking Medicine Technology: